Abstract
Oncolysates, debris of tumor cells, have been proven to be effective in active immunotherapy of cancer. In this experiment, the oncolysates from murine melanoma cells B16-F10 transfected by recombinant vaccinia viruses encoding human IL-2(IL-2VBO) were used as vaccine. After treatment of tumor bearing mice with pulmonary metastases by intravenous injection of IL-2VBO or rVV-IL-2, higher level IL-2 activity was detected in the serum of IL-2VBO or rVV-IL-2 treated mice at 8h. Further experiment results demonstrated that IL-2VBO significantly reduced the number of pulmonary metastases and prolonged the survival time of tumor-bearing mice when compared with other preparations. Fresh peripheral blood lymphocytes from IL-2VBO treated mice showed potent cytotoxicity to B16-F10 cells and YAC-1 cells. But only cytotoxicity to B16-F10 cells is more marked than that in rVV-IL-2 group, indicating that the IL-2VBO could induce specific and non specific anti-tumor immunity. Because IL-2 expression was at the same level in the serum of IL-2VBO or rVV-IL-2 treated mice, the results suggested that the specific anti-tumor immunity induced by IL-2VBO might contribute to the enhanced therapeutic effect of IL-2VBO.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brown F, Schild GC and Ada GL. Recombinant vaccinia viruses as vaccine. Nature 1986; 319:549.
Lee SS, Eisenlohr LC, McCue PA, et al. Intravesical gene therapy:In vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994; 54:3325.
Acres B, Dott K, Stefani L, et al. Directed cytokine expression in tumor cellsin vivo using recombinant vaccinia virus. Therapeutic Immunology 1994; 1:17.
Giavedoni LD, Jones L, Murray B, et al. Vaccinia virus recombinant expressing chimeric proteins of human immunodeffiency virus and Y - interferon are attenuated for nude mice. Proc Natl Acad Sci USA 1992; 89:3409.
Elkins KL, Ennist DL. Winegar RK, et al.In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevens tumor development in mice. Hum Gene Ther 1994; 5:809.
Ju DW, Cao X, Acres B. Intratumoral injection of GM-CSF-gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther 1997; 4:139.
X Cao, W Zhang, S Gu, et al. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low dose interleukin-2. J Cancer Res Clin Oncol 1995; 121:721.
Wallack MK and Sivanandham M. Clinical trials with VMO for melanoma, Specific immunotherapy of cancer with vaccine. Ann NY Acad Sci 1993; 690:178.
T Wan, X Cao, DW Ju, et al.In vivo gene therapy of murine melanoma mediated by recombinant vaccinia virus encoding human IL-2 gene. Int J Oncol 1997; 10:703.
Estin CD, Stevenson US, Plowman GD, et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA 1988; 85:1052.
Tsang KY, Sam Zaremba, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA Vaccine. J Natl Cacer Inst 1995; 87:982
Author information
Authors and Affiliations
Additional information
This work was supported by a grant from the National Natural Science Foundation of China (No.39570668).
Rights and permissions
About this article
Cite this article
Wan, T., Cao, X., Ju, D. et al. Anti-metastatic effect of oncolysates from murine melanoma cells transfected with recombinant vaccinia virus encoding human IL-2. Chin J Cancer Res 9, 258–262 (1997). https://doi.org/10.1007/BF02974970
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02974970